- Home
- INO vs FLYX Comparison
INO vs FLYX Comparison
Compare INO & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INO | FLYX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 106.4M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | INO | FLYX |
|---|---|---|
| Price | $1.64 | $2.11 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 695.8K | 468.5K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,220,086.00 | N/A |
| Revenue This Year | $24,407.60 | $9.36 |
| Revenue Next Year | $331.40 | $15.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $1.30 | $1.90 |
| 52 Week High | $2.86 | $8.88 |
Technical Indicators
Market Signals| Indicator | INO | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 41.51 |
| Support Level | $1.48 | $1.96 |
| Resistance Level | $1.78 | $2.77 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 53.70 | 11.11 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.